<DOC>
	<DOCNO>NCT01851070</DOCNO>
	<brief_summary>Study double-blind , randomize , placebo control , dose escalate study . The primary objective study evaluate safety , tolerability feasibility single intravenous infusion allogeneic mesenchymal precursor cell ( MPCs ) compare placebo 12 week post-infusion treatment patient active rheumatoid arthritis ( RA ) receive methotrexate +/- DMARDs least 6 month prior screen incomplete response least one TNF-alpha inhibitor .</brief_summary>
	<brief_title>A Multi-center Study Single IV Infusion Allogeneic MPCs Patients With Rheumatoid Arthritis Incomplete Response Least One TNF Alpha Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Males Females age 1880 year old Active rheumatoid arthritis ( RA ) disease per 2010 ACR/EULAR classification criterion diagnosis RA . Must positive rheumatoid factor and/or anticyclic citrullinated peptide ( antiCCP3 ) without extraarticular disease functional limitation Patient active RA define : 4 tender joint ( TJC ) count ( 28 joint count ) screen 4 swollen joint ( SJC ) count ( 28 joint count ) screen ESR ≥ 28 mm/hr OR hsCRP great ULN Patient take MTX least 4 month dose route administration stable least 8 week prior screen Patient inadequate response least one TNFα inhibitor last dose least 6 week prior screen Use oral DMARD ( sulfasalazine , hydroxychloroquine , chloroquine leflunomide ) permit must stable least 3 month prior screen Pregnant woman woman breastfeed . Other investigational therapy receive within 8 week five halflives ( whichever longer ) prior Screening ( except exclusion # 13 ) . Known suspected alcohol drug abuse within three year precede Screening . Autoimmune disease RA ( systemic lupus erythematosus ( SLE ) , mixed connective tissue disease , scleroderma , polymyositis/dermatomyositis , vasculitis ) History current inflammatory joint disease RA ( tophaceous gout , reactive arthritis , psoriatic arthritis , ankylose spondylitis spondyloarthropathy , Lyme disease ) . Patients primarily diagnose osteoarthritis exclude . Bedridden confine wheelchair patient &gt; 3 arthroplasty due RA . History diagnose and/or treat malignancy evidence recurrence past 5 year Surgical procedure plan occur trial ( patient may rescreened follow completion recovery surgical procedure ) . Use TNFα inhibitor treatment RA time screen within 6 week prior screen . Prior use biologic agent treatment RA within 6 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>